Coronavirus vaccine
The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.
1. A method of stimulating an immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising:
(I) a mRNA comprising:
(a) at least one coding sequence which is at least 80% identical to SEQ ID NO: 137 encoding a severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) spike protein (S) at least 90% identical to SEQ ID NO: 10 that is a pre-fusion stabilized spike protein (S_stab) comprising a pre-fusion stabilizing K986P and V987P mutation and comprising a D614G amino acid substitution; and
(b) a 5′ heterologous untranslated region (UTR) and a heterologous 3′ UTR, said heterologous 3′ UTR comprising a terminal poly(A) sequence of 30 to 200 adenosine nucleotides; and
(II) at least one pharmaceutically acceptable carrier,
wherein the mRNA is complexed with lipid nanoparticles (LNP) and wherein the LNP comprise:
(i) at least one cationic lipid according to formula III-3:
(ii) at least one neutral lipid, comprising 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC);
(iii) at least one steroid, comprising cholesterol; and
(iv) at least one polyethylene glycol (PEG)-lipid according to formula IVa:
wherein (i) to (iv) are in a molar ratio of about 20-60% cationic lipid, 5-25% neutral lipid, 25-55% sterol, and 0.5-5% PEG-lipid,
wherein the composition is administered by intramuscular injection.
2. The method of claim 1 , wherein the mRNA comprises at least one coding sequence encoding a SARS-CoV-2 spike protein (S) at least 95% identical to SEQ ID NO: 10.
3. The method of claim 2 , wherein the mRNA comprises a 5′-cap structure.
4. The method of claim 3 , wherein 5′-cap structure comprises a m7G, cap0, cap1, cap2, a modified cap0, or a modified cap1 structure.
5. The method of claim 3 , wherein the mRNA comprises a sequence at least 85% identical to SEQ ID NO: 137.
6. The method of claim 5 , wherein the mRNA comprises a sequence at least 90% identical to SEQ ID NO: 137.
7. The method of claim 1 , wherein the heterologous 3′-UTR comprises or consists of a nucleic acid sequence derived from a 3′-UTR of a gene selected from the group consisting of PSMB3, ALB7, alpha-globin, CASP1, COX6B1, GNAS, NDUFA1, and RPS9.
8. The method of claim 1 , wherein the heterologous 5′-UTR comprises or consists of a nucleic acid sequence derived from a 5′-UTR of a gene selected from the group consisting of HSD17B4, RPL32, ASAH1, ATP5A1, MP68, NDUFA4, NOSIP, RPL31, SLC7A3, TUBB4B, and UBQLN2.
9. The method of claim 3 , wherein the nucleic acid comprises at least one histone stem-loop.
10. The method of claim 3 , wherein 100% of the uracil positions in the at least one coding sequence of the mRNA have a chemical modification.
11. The method of claim 3 , wherein 100% of the uracil positions in the at least one coding sequence of the mRNA are substituted with pseudouridine or N(1)-methylpseudouridine.
12. The method of claim 11 , wherein 100% of the uracil positions in the at least one coding sequence of the mRNA are substituted with N(1)-methylpseudouridine.
13. The method of claim 3 , wherein the mRNA has been purified by a method comprising tangential flow filtration (TFF).
14. The method of claim 13 , wherein the mRNA has been purified by a method comprising TFF and reversed-phase high pressure liquid chromatography (RP-HPLC).
15. The method of claim 12 , wherein the LNP comprise a PEG lipid according to formula IVa:
and wherein n has a mean value ranging from about 30 to 60.
16. The method of claim 15 , wherein the LNP comprise at least one PEG-lipid according to formula (IVa) wherein n has a mean value ranging from about 30±2, 32±2, 34±2, 36±2, 38±2, 40±2, 42±2, 44±2, 46±2, 48±2, 50±2, 52±2, 54±2, 56±2, 58±2, or 60±2.
17. The method of claim 15 , wherein the composition further comprises a lyoprotectant.
18. The method of claim 17 , wherein the lyoprotectant comprises sucrose.
19. The method of claim 15 , wherein the composition has a lipid to RNA molar ratio (N/P ratio) of from about 2 to about 12.
20. The method of claim 15 , wherein the LNP have a mean diameter of from about 60 nm to about 200 nm.
21. The method of claim 20 , wherein the LNP comprise components (i) to (iv) in a molar ratio of approximately 50:10:38.5:1.5 (cationic lipid:neutral lipid:cholesterol:PEG-lipid).
22. The method of claim 20 , wherein the composition comprises about 1 μg to about 200 μg of the mRNA.
23. The method of claim 22 , wherein the composition comprises about 5 μg to about 100 μg of the mRNA.
24. The method of claim 22 , wherein the method comprises administering the composition to the subject at least twice.
25. A method of stimulating an immune response in a subject comprising administering to the subject an effective amount of a composition comprising:
(I) a mRNA comprising from a 5′ to 3′:
(a) the mRNA comprises a 5′-cap structure;
(b) at least one coding sequence which is at least 80% identical to SEQ ID NO: 137 encoding a severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) spike protein (S) at least 95% identical to SEQ ID NO: 10 that is a pre-fusion stabilized spike protein (S_stab) comprising a pre-fusion stabilizing K986P and V987P mutation and comprising a D614G amino acid substitution, wherein 100% of the uracil positions in the at least one coding sequence of the mRNA are substituted with N(1)-methylpseudouridine;
(c) a heterologous 5′ untranslated region (UTR), and a heterologous 3′ UTR; and
(d) a terminal poly(A) sequence comprising 30 to 200 adenosine nucleotides; and
(II) at least one pharmaceutically acceptable carrier, wherein the mRNA is complexed with lipid nanoparticles (LNP) and wherein the LNP comprises:
(i) at least one cationic lipid according to formula III-3:
(ii) 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC);
(iii) cholesterol; and
(iv) at least one polyethylene glycol (PEG)-lipid according to formula IVa:
wherein (i) to (iv) are in a molar ratio of about 20-60% cationic lipid, 5-25% DSPC, 25-55% cholesterol, and 0.5% to 5% PEG-lipid,
wherein the composition is administered by intramuscular injection.
26. The method of claim 25 , further defined as a method of stimulating production of SARS-CoV-2 spike protein-binding antibodies in the subject.
27. The method of claim 26 , wherein the mRNA comprises a sequence at least 85% identical to SEQ ID NO: 137.
28. The method of claim 27 , wherein the LNP have a mean diameter of from about 60 nm to about 200 nm.
29. The method of claim 28 , wherein the composition comprises about 5 μg to about 100 μg of the mRNA.